Researchers in Australia have highlighted the potential of ANGLE PLC (AIM:AGL, OTCQX:ANPCY)’s liquid biopsy system in assessing which small cell lung cancer patients might respond to expensive checkpoint inhibitor drugs.
The team at Edith Cowan University found the company’s Parsortix system provided the level of granularity when assessing circulating tumour cells to make a determination.
Relying on a simple blood draw, Parsortix might at some point provide an alternative to a tissue biopsy, an invasive procedure.
Response rates to so-called PD-L1 or PD-1 inhibitors such as Keytruda or Opdivo can be anywhere from 13% to 50% at a cost of US$170,000 a course.
The findings have been published in the Journal of Translational Lung Cancer Research. For more details click here.